We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ProQR Therapeutics NV | NASDAQ:PRQR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.50% | 1.99 | 1.92 | 2.08 | 2.05 | 1.97 | 2.01 | 30,250 | 22:59:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
February 28, 2017
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Attached as Exhibit 99.1 to this Report on Form 6-K are the unaudited financial statements of ProQR Therapeutics N.V. (the Company) for the three months and year ended December 31, 2016 and attached as Exhibit 99.2 to this Report on Form 6-K is a press release of ProQR Therapeutics N.V. dated February 28, 2017, announcing the Companys results for the three months and year ended December 31, 2016.
The Company hereby incorporates by reference the information contained herein into the Companys registration statement on Form F-3 (File No. 333-207245).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PROQR THERAPEUTICS N.V. | ||||
Date: February 28, 2016 | By: |
/s/ Smital Shah |
||
Smital Shah | ||||
Chief Financial Officer |
INDEX TO EXHIBITS
Number |
Description |
|
99.1 | Unaudited financial statements of ProQR Therapeutics N.V. for the three months and year ended December 31, 2016. | |
99.2 | Press Release of ProQR Therapeutics N.V. dated February 28, 2017, announcing the Companys results for the three months and year ended December 31, 2016. |
1 Year ProQR Therapeutics NV Chart |
1 Month ProQR Therapeutics NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions